IDH1 and central nervous system cancer: IDH1 and IDH2 are mutated in >70% of lower-grade gliomas (grades II and III), in some glioblastomas, and ∼20% of AML, but also in cholangiocarcinoma, chondrosarcoma, and in other cases of different tumor types [92].